Genentech and Biogen Idec said Tuesday that a key study of the drug Rituxan did not meet its main goal of a response in patients with systemic lupus erythematosus, commonly called lupus.

FORBES: Magazine Article

Genentech (nyse: DNA - news - people ) and Biogen Idec (nasdaq: BIIB - news - people ) said Tuesday that a key study of the drug Rituxan did not meet its main goal of a response in patients with systemic lupus erythematosus, commonly called lupus.

FORBES: Lupus Treatment Evades Genentech, Biogen